Kenvue Inc. (NYSE:KVUE) Receives Consensus Recommendation of “Hold” from Analysts

Kenvue Inc. (NYSE:KVUE) has been assigned a consensus rating of “Hold” from the sixteen ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $24.85.

A number of research analysts recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. Royal Bank of Canada lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Sanford C. Bernstein began coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Finally, William Blair began coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock.

Institutional Trading of Kenvue

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Beaumont Financial Advisors LLC boosted its holdings in shares of Kenvue by 3.0% in the fourth quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock valued at $377,000 after acquiring an additional 509 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Kenvue by 51.3% in the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock valued at $33,000 after purchasing an additional 526 shares during the period. Tradition Wealth Management LLC lifted its stake in shares of Kenvue by 2.8% in the fourth quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock valued at $458,000 after purchasing an additional 575 shares during the period. Dfpg Investments LLC lifted its stake in shares of Kenvue by 2.3% in the fourth quarter. Dfpg Investments LLC now owns 26,659 shares of the company’s stock valued at $567,000 after purchasing an additional 589 shares during the period. Finally, Mutual Advisors LLC lifted its stake in shares of Kenvue by 6.1% in the fourth quarter. Mutual Advisors LLC now owns 10,606 shares of the company’s stock valued at $228,000 after purchasing an additional 612 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.6 %

NYSE KVUE opened at $19.02 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average price is $19.84 and its 200 day moving average price is $20.14. Kenvue has a 12 month low of $17.82 and a 12 month high of $27.80.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. Sell-side analysts anticipate that Kenvue will post 1.15 earnings per share for the current year.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.